Researchers at the University of Chicago have developed a "universal" chimeric antigen receptor (CAR) platform that offers ...

In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing ...

A team of researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai has successfully treated ...

Patient dosing has continued to successfully escalate in an early-phase trial of a novel FSHR-targeting CAR T-cell therapy in ...

Financing led by Fidelity Management & Research Company with participation from RiverVest Venture Partners, Lightchain Capital, LYZZ ...

CAR T-cell therapy demand is rising, prompting institutions to expand access and reduce care barriers, exemplified by Vanderbilt-Ingram Cancer Center's outpatient center. Dr. Oluwole emphasizes ...

The newly launched EASYGEN (Easy workflow integration for gene therapy) consortium will develop a fully automated, hospital-based platform capable of manufacturing personalised cell therapies within a ...

A new in vivo approach to chimeric antigen receptor T-cell (CAR-T) therapy could extend the technology’s use beyond cancer, as a treatment for autoimmune disease (Science 2025, DOI: 10.1126 ...

CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce dramatic results when treating blood cancers like lymphoma and leukemia and ...

AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan to add an early-phase autoimmune candidate to its pipeline.